The innovative cancer therapy, RP2, uses a modified herpes virus to combat cancer cells. RP2 harnesses and amplifies the virus's natural ability to target rapidly dividing cells. The re-engineered virus is then used to infiltrate and destroy cancer cells, leaving healthy cells unharmed and triggering an immune response against the tumor.
Preliminary trials have shown promising results. In a phase one trial with 40 advanced cancer patients, 3 out of 9 patients who received only RP2 therapy showed tumor shrinkage. Furthermore, 7 out of 30 patients receiving a combined therapy showed a positive response, with one patient's cancer disappearing entirely. Given that these patients had severe cancers where other treatments had failed, these results are intriguing. With further trials and optimization, RP2 has the potential to revolutionize cancer treatment, positioning the herpes virus as an unlikely but effective weapon against cancer.
Full article here: https://medium.com/@lawsuithelpdesk/revolutionizing-cancer-treatment-the-unprecedented-promise-of-herpes-virus-therapy-abf4b7754c32